Clinical trialNCT07595874RecruitingPhase 2Interventional

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

SponsorCity of Hope Medical CenterEnrollment100Advanced Colon AdenocarcinomaAdvanced Colorectal AdenocarcinomaAdvanced Rectal AdenocarcinomaStage IIB Colon Cancer AJCC v8Stage IIB Rectal Cancer AJCC v8Stage IIC Colon Cancer AJCC v8+7 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Pashtoon M Kasi
City of Hope Medical Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ctca at Western Regional Medical Center
Goodyear, Arizona, United States
Pashtoon M. Kasi
Recruiting
City of Hope Corona
Corona, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope Medical Center
Duarte, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope Seacliff
Huntington Beach, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope at Long Beach Elm
Long Beach, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope South Pasadena
South Pasadena, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope Upland
Upland, California, United States
Pashtoon M. Kasi
Recruiting
City of Hope Atlanta Cancer Center
Newnan, Georgia, United States
Pashtoon M. Kasi
Recruiting
City of Hope at Illinois Chicago Downtown
Chicago, Illinois, United States
Pashtoon M. Kasi
Recruiting
City of Hope at Chicago
Zion, Illinois, United States
Pashtoon M. Kasi
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BalstilimabBotensilimab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Dec 2026
Primary completion: 27 May 2027
Completion: 27 May 2027
Last update posted: 1 Jul 2026
Registered enrollment: 100
Registry id: NCT07595874

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.